Clinical Trials Logo

Diabetic Neuropathy Peripheral clinical trials

View clinical trials related to Diabetic Neuropathy Peripheral.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06201611 Not yet recruiting - Clinical trials for Diabetic Neuropathy Peripheral

Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.

EVANESCENT-DPN
Start date: January 15, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to test in patients with diabetic neuropathy, - Can Nevibolol at a dose of 2.5 mg- 10 mg compared with standard pain modulating treatment conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up. - Can Nevibolol at a dose of 2.5 mg- 10 mg compared with a combination of Alpha Lipoic Acid (600 mg/day)+EPALRESTAT (150 mg/day) conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up - All potential participants will undergo screening- about 10 ml of blood will be drawn to perform the following assesments at screening- HbA1c, FBS,Vit B12, TSH, fT4. - Baseline assessments conducting a nerve conduction study, quality of life assesment using Eq-5D-5L and NRS pain score. - 20% of patients (24 patients) will undergo Sudoscan, Corneal confocal microscopy and a skin biopsy for assessing IENFD (Intra Epidermal Nerve Fibre Density). - 15th day, 1 month and 3rd month followup for evaluating patients status and medication adherance. - 6th month followup for evaluating patients status and medication adherance. Researchers will compare Nebivolol against combination of Epalrestat+Alpha Lipoic Acid against standard pain modulating treatment to evaluate their diseaes modifying effect as reflected by nerve conduction study parameters.

NCT ID: NCT05558878 Not yet recruiting - Clinical trials for Diabetic Neuropathy Peripheral

Effect of Ambroxol in Diabetic Peripheral Neuropathy

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

A prospective, randomized, controlled study will be conducted at Department of Endocrinology, Faculty of Medicine, Ain Shams University, assessing the efficacy of Ambroxol addition on the clinical outcome and inflammatory markers in Diabetic peripheral neuropathy patients

NCT ID: NCT05461274 Not yet recruiting - Clinical trials for Diabetic Neuropathies

Determining Patterns In Trial Experiences of Diabetic Neuropathy Patients

Start date: August 2024
Phase:
Study type: Observational

Historically, participation in clinical studies is highly skewed towards particular demographic groups of people. This study will invite several participants to gather a wide range of information on clinical trial experiences for diabetic neuropathy patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of diabetic neuropathy. The data collected from this study will help improve future outcomes for all diabetic neuropathy patients as well as those in under-represented demographic groups.